Voluntis and AstraZeneca Win Prestigious Prix Galien MedStartUp Award for ‘Best Patient Engagement Technologies’ for eCO
https://www.businesswire.com/news/home/20181028005032/en/
PARIS--(BUSINESS WIRE)--Oct 29, 2018--Regulatory News:
Voluntis (Euronext Paris, Ticker: VTX - ISIN: FR0004183960) (Paris:VTX), a company specialized in digital therapeutics, and AstraZeneca (NYSE: AZN) announced that they have been awarded the 2018 Prix Galien – MedStartUp Award for Best Patient Engagement Technology for eCO. The award recognizes outstanding partnerships between French and North American entities to improve health care. It was presented at a ceremony in New York City on October 25, 2018.